Abstract

Apixaban 0.25-mg/mL Suspension for Enteral Feeding Tube

Author(s): Allen Loyd V Jr

Issue: Jul/Aug 2021 - Volume 25, Number 4

Page(s): 320

Download in electronic PDF format for $75

Abstract

A formulation for preparing Apixaban 0.25-mg/mL Suspension for Enteral Feeding Tube. Includes ingredients, method of preparation, discussion, and references for the compounding pharmacist.

Related Keywords

Related Categories

Printer-Friendly Version

Related Articles from IJPC

Issue/Page View/Buy	Title/Author (Click for Abstract / Details / Purchase)
Jul/Aug 2021 Pg. 320	Apixaban 0.25-mg/mL Suspension for Enteral Feeding Tube Author(s): Allen Loyd V Jr
May/Jun 2022 Pg. 214-217	Basics of Compounding: Vehicle for Drug Administration via Enteral Feeding Tubes Author(s): Allen Loyd V Jr
May/Jun 2010 Pg. 250-256	Compounding Rifampin Suspensions with Improved Injectability for Nasogastric Enteral Feeding Tube Administration Author(s): de Villiers Melgardt M, Vogel Laura, Bogenschutz Monica C, Fingerhut Bonnie J, D'Silva Joseph B, Moore Anne
Jul/Aug 2010 Pg. 276-282	Recommendations for Compounding Medications for Feeding Tube Administration Author(s): Klang Mark
May/Jun 2004 Pg. 181-185	Compounding in the Pharmacy Curriculum: Beyond the Basics Author(s): Hinkle Amanda R, Newton Gail D
May/Jun 2003 Pg. 206-207	Technology Spotlight: Tube Sealers Author(s): Jones Michael, Adams Susan
Jul/Aug 2000 Pg. 304	Nasogastric Tube/Percutaneous Endoscopic Gastrostomy Tube Suspension Formula Author(s): Allen Loyd V Jr
Nov/Dec 2004 Pg. 462-465	Basics of Compounding for Cough Author(s): Allen Loyd V Jr
Nov/Dec 2016 Pg. 510	Imatinib 40-mg/mL Oral Suspension Author(s): Allen Loyd V Jr
Sep/Oct 2022 Pg. 358-362	Hazardous Drug Enteral Device: A Closed System Device for Crushing and Dispersing Hazardous Drug Tablets for Enteral Administration Author(s): Lopez C Vidal, Rios GL Quito
Mar/Apr 2011 Pg. 124-128	Proton Pump Inhibitor Homogenous Suspensions: A Compounding Solution to Pediatric Gastroesophageal Reflux Disease Author(s): Corsini Lindsay, Williams LaVonn A
Jul/Aug 2021 Pg. 321	Atomoxetine 4-mg/mL Oral Solution/Suspension Author(s): Allen Loyd V Jr
Nov/Dec 2022 Pg. 446-466	Compounding with Biotechnology Products, Part 2: Product-specific Considerations Author(s): Allen Loyd V Jr
Sep/Oct 2023 Pg. 420	Nitazoxanide 20-mg/mL Oral Suspension Author(s): Allen Loyd V Jr
Nov/Dec 2021 Pg. 503	Metoprolol Tartrate 10 mg/mL in SyrSpend SF pH4 Oral Suspension Author(s): Allen Loyd V Jr
Jul/Aug 2009 Pg. 314-317	Poster Presentation Report: Safety of Maternal Testosterone Therapy During Breast Feeding Author(s): Glaser Rebecca L, Newman Mark, Parsons Melanie, Zava David, Glaser-Garbrick Daniel
Sep/Oct 2003 Pg. 389-393	Formulation and Accelerated Stability Studies for an Extemporaneous Suspension of Amiodarone Hydrochloride Author(s): Alexander Kenneth S, Thyangarajapuram N
Jul/Aug 2002 Pg. 255-256	Aminophylline 3%, Co-dergocrine Mesylate 0.05%, and Isosorbide Dinitrate 0.25% Cream for the Treatment of Orgasmic Dysfunction in Women Author(s): Mason Dave
Jan/Feb 2021 Pg. 43	Amlodipine Besylate 0.5-mg/mL to 10-mg/mL in SuspendIt Oral Suspension Author(s): Allen Loyd V Jr
Jan/Feb 2021 Pg. 44	Clonidine 0.01-mg/mL in Oral Mix and Oral Mix SF Suspension Author(s): Allen Loyd V Jr